{"id":409816,"date":"2025-03-07T00:00:00","date_gmt":"2025-03-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0027-2025-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-lennox-gastaut-syndrome-us\/"},"modified":"2026-03-31T10:26:47","modified_gmt":"2026-03-31T10:26:47","slug":"cutrcg0027-2025-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-lennox-gastaut-syndrome-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0027-2025-biopharma-epilepsy-current-treatment-current-treatment-physician-insights-lennox-gastaut-syndrome-us\/","title":{"rendered":"Epilepsy &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Lennox-Gastaut Syndrome (US)"},"content":{"rendered":"<p>Lennox-Gastaut syndrome (<abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr>) is a severe pediatric-onset epilepsy syndrome characterized by developmental delays or regression, multiple seizure types, and electroencephalographic abnormalities. Eight antiepileptic drugs (<abbr data-abbreviation-entity=\"4723\" title=\"antiepileptic drug\">AED<\/abbr>s), including Epidiolex, Fintepla, rufinamide, and clobazam, are approved for the adjunctive treatment of LGS, while others, such as levetiracetam, are often used off-label. Despite these options, full seizure control remains elusive for most patients, even with combination treatment. Neurologists must carefully weigh many factors when selecting an <abbr data-abbreviation-entity=\"4723\" title=\"antiepileptic drug\">AED<\/abbr>, often tailoring treatment through dose adjustments, additions, or switches between therapies to optimize seizure management in this vulnerable population. This report explores the factors influencing prescribers\u2019 decision-making in managing <abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr>, examines their views on current treatment options, analyzes prescribing patterns, and highlights critical areas where unmet needs persist.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What attributes drive the current prescribing patterns, recent anticipated changes in drug choice, and overall decision-making in <abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr>?<\/li>\n<li>Which therapies are dominant in the first, second, and third lines? What are the drivers and obstacles to using key brands, and what are the reasons for their discontinuation?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"5075\" title=\"Lennox-Gastaut syndrome\">LGS<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most used combinations?<\/li>\n<li>How has the availability of Epidiolex and Fintepla changed the prescribing of first- and second-generation therapies?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of <span>105<\/span>\u00a0U.S. neurologists, pediatric neurologists, and epileptologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Epidiolex, clobazam, clonazepam, felbamate, Fintepla, lamotrigine, levetiracetam, rufinamide, topiramate, and valproate<\/p>\n<p><strong>Key analyses<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-409816","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-epilepsy","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409816\/revisions"}],"predecessor-version":[{"id":410121,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409816\/revisions\/410121"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=409816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}